Predicting risk of prostate specific antigen recurrence after radical prostatectomy with the Center for Prostate Disease Research and Cancer of the Prostate Strategic Urologic Research Endeavor databases.

[1]  J. Moul.  Prostate specific antigen only progression of prostate cancer. , 2000, The Journal of urology.

[2]  K I Bland,et al.  Clinical highlights from the National Cancer Data Base, 2000 , 2000, CA: a cancer journal for clinicians.

[3]  P. Carroll.  Prostate biopsy: a wealth of information when done and interpreted correctly. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  A. Renshaw,et al.  Clinical utility of the percentage of positive prostate biopsies in defining biochemical outcome after radical prostatectomy for patients with clinically localized prostate cancer. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  J. Manola,et al.  Immediate hormonal therapy compared with observation after radical prostatectomy and pelvic lymphadenectomy in men with node-positive prostate cancer. , 1999, The New England journal of medicine.

[6]  J. Serth,et al.  Article no. bjoc.1999.0806 , 2022 .

[7]  J. Moul,et al.  Statistical modeling using preoperative prognostic variables in predicting extracapsular extension and progression after radical prostatectomy for prostate cancer. , 1998, Military medicine.

[8]  J. Moul,et al.  CD34 immunohistochemical assessment of angiogenesis as a prognostic marker for prostate cancer recurrence after radical prostatectomy. , 1998, The Journal of urology.

[9]  M. Kattan,et al.  A preoperative nomogram for disease recurrence following radical prostatectomy for prostate cancer. , 1998, Journal of the National Cancer Institute.

[10]  J. Moul,et al.  Biostatistical modeling using traditional preoperative and pathological prognostic variables in the selection of men at high risk for disease recurrence after radical prostatectomy for prostate cancer. , 1998, The Journal of urology.

[11]  A W Partin,et al.  Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update. , 1997, JAMA.

[12]  H. Levin,et al.  Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy. , 1997, International journal of radiation oncology, biology, physics.

[13]  J. Moul,et al.  Biostatistical modeling using traditional variables and genetic biomarkers for predicting the risk of prostate carcinoma recurrence after radical prostatectomy , 1997, Cancer.

[14]  M W Kattan,et al.  Evaluation of a Nomogram used to predict the pathologic stage of clinically localized prostate carcinoma , 1997, Cancer.

[15]  D. Lubeck,et al.  The CaPSURE database: a methodology for clinical practice and research in prostate cancer. CaPSURE Research Panel. Cancer of the Prostate Strategic Urologic Research Endeavor. , 1996, Urology.

[16]  F. Mostofi,et al.  Elevated levels of apoptosis regulator proteins p53 and bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. , 1996, The Journal of urology.

[17]  D C Young,et al.  An algorithm for predicting nonorgan confined prostate cancer using the results obtained from sextant core biopsies with prostate specific antigen level. , 1996, The Journal of urology.

[18]  J W Moul,et al.  Ki-67 expression is a prognostic marker of prostate cancer recurrence after radical prostatectomy. , 1996, The Journal of urology.

[19]  A. Tewari,et al.  The role of transrectal ultrasound-guided biopsy-based staging, preoperative serum prostate-specific antigen, and biopsy Gleason score in prediction of final pathologic diagnosis in prostate cancer. , 1995, Urology.

[20]  A. D'Amico,et al.  A multivariate analysis of clinical and pathological factors that predict for prostate specific antigen failure after radical prostatectomy for prostate cancer. , 1995, The Journal of urology.

[21]  F. Marshall,et al.  Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. , 1995, Urology.

[22]  P. Scardino,et al.  The new american joint committee on cancer and international union against cancer tnm classification of prostate cancer , 1994, Cancer.

[23]  E. Kaplan,et al.  Nonparametric Estimation from Incomplete Observations , 1958 .

[24]  Taylor Murray,et al.  Cancer statistics, 2000 , 2000, CA: a cancer journal for clinicians.

[25]  Myron Tanncnbaum,et al.  Urologic pathology: The prostate , 1977 .

[26]  D. Cox.  Regression Models and Life-Tables , 1972 .